Showing results (361-370 of 383) with videos related to

Sort By:
Pageof 39
Annals of Neurology|May 23, 2024
Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple SclerosisRosa Cortese, Marco Battaglini, Ferran Prados, et al.
Neuroimage|October 10, 2018
Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networksCharley Gros, Benjamin De Leener, Atef Badji, et al.
Neurology|September 4, 2025
Deep Learning Modeling to Differentiate Multiple Sclerosis From MOG Antibody-Associated DiseaseRosa Cortese, Francesco Sforazzini, Giordano Gentile, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 7, 2023
Development and validation of a REcurrent Liver cAncer Prediction ScorE (RELAPSE) following liver transplantation in patients with hepatocellular carcinoma: Analysis of the US Multicenter HCC Transplant ConsortiumBenjamin V Tran, Dimitrios Moris, Daniela Markovic, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 24, 2026
Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centersPierre-Louis Benveniste, Laurent Létourneau-Guillon, David Araujo, et al.
Annals of Surgery|July 27, 2022
Novel Benchmark Values for Redo Liver Transplantation: Does the Outcome Justify the Effort?Fariba Abbassi, Daniel Gero, Xavier Muller, et al.
BMJ Open|September 16, 2024
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis (MS-STAT2): protocol for a multicentre, randomised controlled, double-blind, phase 3 clinical trial in the UKJames Blackstone, Thomas Williams, Jennifer M Nicholas, et al.
Health Technology Assessment (Winchester, England)|June 29, 2026
Evaluating the effectiveness of simvastatin in slowing the progression of disability in secondary progressive multiple sclerosis: a synopsis of MS-STAT2, a multicentre, randomised controlled, double-blind, phase 3 clinical trialThomas Williams, James Blackstone, Nevin John, et al.
Lancet (London, England)|October 4, 2025
Effect of repurposed simvastatin on disability progression in secondary progressive multiple sclerosis (MS-STAT2): a phase 3, randomised, double-blind, placebo-controlled trialJeremy Chataway, Thomas Williams, James Blackstone, et al.
The Lancet. Neurology|September 20, 2025
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteriaXavier Montalban, Christine Lebrun-Frénay, Jiwon Oh, et al.
Pageof 39